EssilorLuxottica: A Lifetime Holding — at What Price? — MITUXA

Visual health offers durable demand. The question is how much of that growth will reach each shareholder.

Analysis prepared on 9 October 2026; published on 10 October 2026. Market reference: 8 October 2026. Reported figures are attributed to the numbered sources below. Interpretations and valuation assumptions are MITUXA View; no consensus estimates are used.

A need that spans generations

Some businesses solve a need that is immediately understandable. Reading, working, driving and recognising a face are part of everyday life. That makes EssilorLuxottica interesting for a patient investor: its business addresses a need that does not depend on a technology trend.

The idea of a dependable long-term holding expresses this search for continuity. It does not mean an absence of risk or a guaranteed return. Resilient demand can support a business for decades without making its shares attractive at any price.

Our thesis is positive on the durability of visual health. Our reservations concern the price of that durability, the capital needed to develop it and the profitability of newer activities.

The group's strength: connecting several stages of the purchase

EssilorLuxottica combines lens technologies such as Varilux, Transitions and Stellest, brands such as Ray-Ban and Oakley, and distribution networks. Its traditional optical business grew at a mid-single-digit rate in the first half of 2026. [2]

Our interpretation is that this integration helps bring innovation to market: the group can participate in lenses, frames and the sale to the consumer. Distribution does not, however, create a captive customer base. It must keep convincing eye-care professionals and families.

Vision correction must also be distinguished from discretionary spending. A person can hardly forgo a necessary prescription indefinitely. They can, however, choose a cheaper frame or postpone buying sunglasses. The defensive character of the business therefore varies by product.

Myopia: a structural driver, not automatic growth

A meta-analysis of 276 studies covering approximately 5.4 million participants estimates that myopia prevalence among children and adolescents increased from approximately 24% in 1990–2000 to 36% in 2020–2023. It projects almost 40% by 2050. These estimates involve uncertainty and substantial geographical differences. [3]

Investors need to distinguish two markets: correcting vision and seeking to slow the progression of myopia. The latter can support adoption of specialised lenses, provided effectiveness, availability and price allow sustained prescription and use.

The FDA authorised Stellest in the United States in September 2025 to correct myopia and slow its progression in children aged 6 to 12 at the start of treatment. This was the first US authorisation of eyeglass lenses for this indication. It does not mean a cure or permanent commercial exclusivity. [4]

Growth in prevalence must not be confused with growth in sales. The number of children, screening, access to care, financial coverage and adoption of specialised lenses also matter. Our hypothesis is that adoption and access may be as important as demographic change.

The group's myopia-management portfolio grew 22% at constant exchange rates in 2025 and 24% in the second quarter of 2026. Its size and margin are not sufficiently isolated in the documents reviewed to assign it a standalone valuation. [1][2]

As a purely illustrative example, a business representing 5% of sales and growing 20%, with the remainder growing 4%, would bring total growth to 4.8%. That 5% weight is not an estimate of the actual business. It shows why the starting size matters as much as the growth rate.

ZEISS and HOYA: demand will be shared

Visual health attracts credible competitors. ZEISS presents two-year clinical results for MyoCare in European children. HOYA reports high-single-digit growth in its eyeglass lenses business for the fiscal year covered in its 2026 integrated report, supported in particular by MiYOSMART and sales to optical chains. [5][6]

These developments demonstrate active competition. They do not allow products to be ranked by effectiveness: comparing percentages from different trials, populations and protocols would be misleading.

MITUXA View: EssilorLuxottica's advantage rests on a combination of technology, brands and distribution. It needs to be maintained; we assume no permanent clinical superiority.

We will monitor prescriber preference, service to opticians, the price paid by families and the ability to renew products. Competitors can also win customers from smaller manufacturers: their growth does not automatically demonstrate a loss of EssilorLuxottica market share.

The economic risk is having to spend progressively more to defend the same sales. A category can remain attractive while becoming less profitable for its suppliers.

Meta: an opportunity with commitments already attached

The Meta collaboration combines EssilorLuxottica's optical expertise, brands and distribution with its partner's technology. The agreement announced in September 2024 extends the collaboration into the following decade; further joint products were announced in 2026. None of the sources reviewed announces a separation. Full termination and economic-sharing terms are not public in the announcement examined. [7][8]

A separation could nevertheless cause lost sales, transition costs and lower utilisation of dedicated investments. The effect on the share price could exceed the immediate earnings decline if investors sharply revised their growth expectations.

Another risk is a lasting collaboration that becomes less rewarding for EssilorLuxottica. If technology becomes more important in the purchase decision, bargaining power could shift. This is a risk scenario, not an established development.

We therefore identify three situations to test: a profitable partnership, a partnership with disappointing margins and a separation involving transition costs. Without sufficient segment data, we do not attach artificial numerical precision to their impact.

Smart glasses are not a free option: the group commits resources to them. A convincing long-term investment thesis needs to withstand outcomes below technological ambitions.

Growth is not enough: look at earnings per share

In 2025, sales increased 7.5%, but earnings attributable to shareholders fell 1.9%. The adjusted operating margin at current exchange rates declined from 16.7% to 15.7%. The group cited US tariffs and the weight of connected products among the pressures on margins. [1]

This does not condemn the expansion. A new business can need time to reach satisfactory profitability. But shareholders need to understand whether they are funding a transition or a permanently less rewarding model.

Adjusted earnings exclude, among other items, acquisition-related accounting effects and certain compensation or restructuring costs. [1] We distinguish these categories: amortisation without an immediate cash outflow deserves a different analysis from an economic expense associated with employees. The acquisition purchase price remains capital that was actually committed.

Cash flow requires a careful reading

Reported free cash flow for 2025 was €2.796 billion, approximately €6.02 per share using the annual diluted average share count. This consolidated cash flow cannot be equated in full with economic cash attributable solely to shareholders of the parent company. [1]

In the first half of 2026, free cash flow increased from €959 million to €1,067 million. Operating cash flow was virtually flat at €2,169 million; investment net of disposals fell from €721 million to €591 million. The free-cash-flow definition now incorporates asset disposals, with the half-year comparison restated. Net debt, including leases, was 2.0 times trailing twelve-month EBITDA. [2]

Our interpretation: higher free cash flow is positive, but does not yet demonstrate structurally better conversion of sales into cash. Investment needs to preserve manufacturing capacity, stores and innovation.

Minority interests and share-based compensation also require consistent treatment. Dividends paid to minorities do not necessarily measure their economic share of cash. For share-based compensation, we must avoid counting the same cost twice through both a full deduction and a corresponding dilution assumption.

Valuation: what our scenarios actually tell us

Our market reference is €143 on 8 October 2026, based on the Euronext Paris closing quotation recorded during preparation of the research. This is not a live share price. [9]

Our first test assumes €5.80 of economic cash per share in year one, followed by 7% annual growth through year five and 2.5% perpetual growth. Cash flows are discounted at year-end. The €5.80 starting point is an exploratory assumption still requiring reconciliation, not a reported metric or consensus estimate.

At required returns of 8%, 9% and 10%, this calculation produces approximately €123, €104 and €89 per share, respectively.

Extending 7% growth through year ten, with other assumptions unchanged, lifts the result at a 9% required return from approximately €104 to €120. Growth duration matters greatly; demographic trends alone do not establish ten years of per-share cash growth at that rate.

These calculations assume cash flows after interest, investment, operating requirements and lease payments, with sustainable financing. A valuation of cash flows to equity should not then mechanically deduct all debt a second time. However, repayments required to stabilise financing must be incorporated into cash flows.

These figures are sensitivities, not a validated fair-value range. They do not separate traditional activities from those associated with Meta, and include no explicitly quantified separation cost. A substantial part of their value depends on the terminal value.

We therefore adopt no purchase threshold. Applying a 25% margin of safety to an uncertain starting point would create unjustified precision.

Our decision: monitor value creation, not just sales

Our view is WATCH, with moderate conviction in the investment opportunity and a five-to-ten-year horizon. Visual health and myopia control make the company relevant to a long-term portfolio. Competition, financing and technological dependence nevertheless limit the reassurance offered by the label of a dependable family holding.

We would become more positive with sustained growth in economic cash per share, stabilised debt, adequately rewarded investment and a price offering a margin of safety on verifiable assumptions.

The thesis would weaken if the group had to sacrifice margins permanently to defend its position, accumulated inadequately rewarded commitments or became increasingly dependent on a partner without improving its share of profits. A falling share price alone would not solve those problems.

The need to see better is durable. Investment quality depends on the price paid and the wealth retained by each shareholder.

Sources and scope

Reported information is attributed to its sources. Interpretations, calculations and scenarios are MITUXA's own; no consensus figures are used in the valuation. Manufacturers' clinical communications do not constitute an independent comparison between products. The analysis does not incorporate third-quarter 2026 results. Normalised cash flow, profitability by activity and detailed Meta partnership terms remain limitations of the study.

Independent research. This content is not personalised investment advice. Scenarios do not guarantee returns.

Explore our research at mituxa.com and subscribe to MITUXA on Substack. Contact: questions@mituxa.com.

MITUXA — Beyond the Obvious